Want to see SLS full AI Analyst Report?
SLS Stock Chart & Stats
$11.32
-$1.02(-8.27%)
At close: 4:00 PM EDT
$11.32
-$1.02(-8.27%)
Day’s Range― - ―
52-Week Range$1.39 - $15.88
Previous CloseN/A
Volume6.73M
Average Volume (3M)9.61M
Market Cap
$1.88B
Enterprise Value$623.27
Total Cash (Recent Filing)$107.20M
Total Debt (Recent Filing)$871.00K
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume6,840,242
30 Day Avg. Volume9,611,115
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside142.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Low Debt And Stronger EquityExtremely low debt and a materially improved equity base give SELLAS durable financial flexibility to fund clinical programs without heavy interest burdens. This reduces near-term bankruptcy risk, supports R&D investments, and improves ability to negotiate partnerships over the coming months.
Material Liquidity Boost From Warrant ExercisesA sizeable cash position reinforced by $28.7M of warrant exercise proceeds materially extends operational runway for clinical development. That non-debt liquidity reduces immediate financing pressure and allows the company to advance trials and regulatory work with less short-term fundraising risk.
Non-dilutive Milestone Potential Via LicenseA partner-backed Greater China license carrying up to $191.5M in milestones represents substantial potential non-dilutive funding and validation. Continued partner commercialization can accelerate revenue realization in a major market and de-risk portions of development funding and commercial execution.
Bears Say
No Meaningful Revenue; Persistent LossesThe absence of meaningful revenue and ongoing large net losses mean SELLAS lacks internal cash generation to fund operations. This structural unprofitability forces dependence on external capital and limits ability to absorb R&D spend, constraining sustainable growth without dilution or partnerships.
Consistent Negative Operating Cash FlowSustained negative operating and free cash flow creates recurring financing needs. Over a multi-month horizon, this reliance increases dilution risk and can force timing or scope changes to clinical programs if capital markets tighten, making strategy execution contingent on external funding.
Adverse Arbitration Ruling And Reduced Commercial ControlThe arbitration loss creates immediate legal costs and cedes commercialization momentum in Greater China to the licensee. That reduces SELLAS's ability to directly capture market returns and may limit strategic options and future bargaining power in a key region, a lasting operational constraint.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $1.39 and its highest was $15.88 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $1.88B.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.01.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 186,032,580 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 25.096%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (142.93% Upside)
$27.50 (142.93% Upside)
Blogger Sentiment
Bullish
SLS Sentiment 91%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
518.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
226.63%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company’s pipeline is centered on peptide-based immunotherapies and related oncology programs, with its lead clinical candidate being galinpepimut-S (GPS), an investigational WT1-targeting cancer immunotherapy evaluated across multiple cancer indications, and an additional program commonly referred to as nelipepimut-S (NPS).
SLS Stock 12 Month Forecast
Average Price Target
$27.50
▲(142.93% Upside)
Technical Analysis
Xencor
―
Iovance Biotherapeutics
―
Arvinas Holding Company
―
Oric Pharmaceuticals
―
Nanobiotix
―
Ownership Overview
1.80% Insiders
6.63% Mutual Funds
1.13% Other Institutional Investors
74.86% Public Companies and
Individual Investors